間質性膀胱炎／疼痛性膀胱症候群患者におけるタネズマブの有効性を調査する研究

基本情報

NCT ID

NCT00999518

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

205

治験依頼者名

Pfizer

概要

In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)